Jawad Kiani, MD
Cardiovascular Disease · Las Vegas, NVNPI 1588975544
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (46.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Abbott at 55.2% of the total. 2025 is the largest year on record at $37,942, more than ten times the $3,244 reported in 2019. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $268.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$40K
- Edwards Lifesciences$13K
- Boston Scientific$7K
- Medtronic$3K
- Penumbra, Inc.$3K
- Angiodynamics, Inc.$2K
- plus $5K from 17 others
What the payments were for
- Consulting fees$3,4885%
- Speaking & faculty fees$5,1607%
- Grants$33,83946%
- Travel & lodging$11,95416%
- Food & beverage$18,52825%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 67 | $40,364 |
| Edwards Lifesciences | 53 | $12,737 |
| Boston Scientific | 26 | $6,913 |
| Medtronic(2 entities) | 35 | $3,073 |
| Penumbra, Inc. | 14 | $2,789 |
| Angiodynamics, Inc. | 9 | $2,469 |
| Abiomed | 25 | $1,298 |
| Baylis Medical Company Inc | 2 | $780 |
| W. L. Gore & Associates, Inc. | 5 | $576 |
| Shockwave Medical, Inc | 3 | $386 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $279 |
| Siemens Medical Solutions USA, Inc. | 3 | $263 |
| Impulse Dynamics (USA) Inc. | 3 | $237 |
| Biosense Webster, Inc. | 2 | $219 |
| Cvrx, Inc. | 1 | $195 |
| Stryker | 1 | $169 |
| Johnson & Johnson | 5 | $107 |
| Chiesi USA, Inc. | 1 | $84 |
| Amgen | 1 | $77 |
| Novartis | 1 | $27 |
| Surmodics, Inc. | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Philips North America LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$35,692
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$5,395
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,037
- AngioVac$2,308
- EVOQUE$1,697
- Indigo System$1,602
- Watchman$1,006
- TRICLIP$840
- Mitra Clip system$786
- NRG needle$780
- HawkOne$663
- Impella$630
- Valiant Captivia$523
- Indigo$505
- CoreValve Evolut$442
- MitraClip System$425
- GORE CARDIOFORM Septal Occluder$382
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$367
- XACT$338
- OPTIMIZER$334
How this compares
$73,098 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 70 | $100,694 |
| EliquisApixaban | 79 | $92,233 |
| JardianceEmpagliflozin | 49 | $77,864 |
| FarxigaDapagliflozin Propanediol | 60 | $65,762 |
| OzempicSemaglutide | 16 | $27,488 |
| BrilintaTicagrelor | 41 | $24,808 |
| XareltoRivaroxaban | 21 | $23,882 |
| Repatha SyringeEvolocumab | 13 | $12,558 |
| Metoprolol Succinate | 242 | $3,101 |
| Atorvastatin Calcium | 137 | $1,245 |
| Ranolazine ErRanolazine | 14 | $1,019 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 69 | $894 |
| Amiodarone Hcl | 12 | $707 |
| ClopidogrelClopidogrel Bisulfate | 87 | $681 |
| Nitroglycerin | 19 | $419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $27 | $100,69470 claims |
| Johnson & JohnsonXarelto | $107 | $23,88221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
- Dalia HawwassLas Vegas$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.